Emily Leproust Sells 356,546 Shares of Twist Bioscience (NASDAQ:TWST) Stock

Twist Bioscience Corporation (NASDAQ:TWST) CEO Emily Leproust sold 356,546 shares of the business’s stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $157.99, for a total value of $56,330,702.54. Following the completion of the sale, the chief executive officer owned 620,589 shares of the company’s stock, valued at $98,046,856.11. The trade was a 36.49% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Twist Bioscience Trading Down 0.7%

Shares of Twist Bioscience stock traded down $1.16 during midday trading on Monday, reaching $165.83. 2,238,774 shares of the company’s stock traded hands, compared to its average volume of 1,556,263. The stock has a 50 day moving average of $118.99 and a 200-day moving average of $83.06. Twist Bioscience Corporation has a 12 month low of $23.30 and a 12 month high of $170.23. The company has a market cap of $10.40 billion, a PE ratio of -74.70 and a beta of 2.22. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.05). Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The company had revenue of $118.38 million during the quarter, compared to analysts’ expectations of $114.55 million. During the same quarter last year, the business earned $0.33 earnings per share. The business’s quarterly revenue was up 23.2% on a year-over-year basis. As a group, equities analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Hedge Funds Weigh In On Twist Bioscience

A number of hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in shares of Twist Bioscience in the 2nd quarter worth $600,191,000. William Blair Investment Management LLC purchased a new stake in shares of Twist Bioscience during the second quarter valued at $223,722,000. Bank of America Corp DE purchased a new stake in shares of Twist Bioscience during the second quarter valued at $94,922,000. Allspring Global Investments Holdings LLC bought a new stake in Twist Bioscience in the 1st quarter worth about $22,563,000. Finally, Bank of New York Mellon Corp bought a new stake in Twist Bioscience in the 2nd quarter worth about $19,722,000.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on TWST shares. Guggenheim reiterated a “buy” rating on shares of Twist Bioscience in a report on Monday, August 24th. Barclays raised their price objective on Twist Bioscience from $65.00 to $95.00 and gave the company an “overweight” rating in a research report on Wednesday, June 24th. BWS Financial reiterated a “sell” rating and set a $45.00 price objective on shares of Twist Bioscience in a research note on Friday. TD Cowen reissued a “buy” rating on shares of Twist Bioscience in a report on Monday, August 3rd. Finally, Canaccord Genuity Group increased their target price on Twist Bioscience from $90.00 to $120.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $103.00.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA using a proprietary silicon-based platform. The company serves researchers and organizations in biotechnology, pharmaceutical development, agriculture, industrial chemicals and academic research.

Its products include synthetic genes, gene fragments, oligonucleotides and DNA libraries used in research, drug discovery, diagnostics development and other applications. Twist also provides next-generation sequencing tools and products, including target-enrichment and sample-preparation solutions, as well as synthetic biology services that support the design and testing of biological systems.

Twist was founded in 2013 and is headquartered in South San Francisco, California.